GlaxoSmithKline (GSK), the manufacturer of rosiglitazone (Avandia®), is facing a lawsuit in America claiming that it misled investors and withheld drug safety information.
PharmaTimes provides more details about the lawsuit. In particular this report notes that GSK performed their own meta-analysis that was submitted to the Food and Drugs Administration (FDA) in August 2006 that shows an increased risk of heart attacks. It is claimed that this information was "never adequately disclosed to the investing public". This claim may relate to the previously reported interim-analysis of the RECORD study.
Action: Media coverage of this lawsuit is likely to encourage patients taking rosiglitazone to consult about the risks and benefits of continued treatment.
|« SMC accept Symbicort SMART||FDA reject rimonabant »|